

INOVIQ CSO CO-AUTHORS SCIENTIFIC STATEMENT ON EXOSOMES

- A Scientific Statement, co-authored by INOVIQ's Chief Scientific Officer, Professor Greg Rice, has been published by the Endocrine Society
- The Statement outlines the emerging role of extracellular vesicles (EVs) in the field of endocrinology and the potential application of EVs as biomarkers for disease
- INOVIQ's patented EXO-NET platform captures EVs from body fluids, providing a fast, efficient, and scalable method for EV biomarker discovery and diagnostic applications

Melbourne, Australia, 26 April 2022: INOVIQ Limited (ASX:IIQ) (**INOVIQ** or the **Company**) is pleased to announce that a Scientific Statement co-authored by the Company's Chief Scientific Officer, Professor Greg Rice, titled "*Extracellular vesicles and their emerging roles as cellular messengers in endocrinology: An Endocrine Society Scientific Statement*" has been published in the high impact scientific journal *Endocrine Reviews*.

Extracellular vesicles (EVs), including exosomes, are lipid membrane bound vesicles released by most cells, including primary or metastatic tumour cells, into biological fluids such as serum, plasma, urine, and saliva.

INOVIQ CSO Dr Greg Rice said, "The Endocrine Society Scientific Statement presents the scientific rationale for incorporating the extracellular vesicle signalling systems into the field of endocrinology and provides guidance for future EV research. Recognition that EV signalling is an integral part of the endocrine system opens up a whole new area of research on how cells regulate bodily functions such as growth and development. Not only do EVs provide us with new insights in this area but also opportunity to use EVs for diagnostic and therapeutic purposes." Dr Rice continued, "Research has confirmed that the analysis of EVs, specifically exosomes, can indicate the presence of a range of cancers, thereby representing an exciting new avenue of cancer diagnosis. Furthermore, the analysis of biomarkers associated with exosomes in blood offers a minimally invasive route for cancer screening, diagnosis, and prognosis."

While the use of EVs as biomarkers of disease has shown promising potential, translation into clinical diagnostic tests has been limited by the availability of simple, rapid, high-throughput isolation methods that deliver suitably enriched preparations of exosomes for use in a routine clinical workflow.

INOVIQ CEO Dr Leeanne Hinch said, "INOVIQ has developed EXO-NET – a rapid, efficient, and scalable method to isolate extracellular vesicles from body fluids. Our proprietary and customisable EXO-NET platform enables EV biomarker discovery and development of exosome-based diagnostic and therapeutic applications. In-house testing and external evaluations have shown that EXO-NET outperformed traditional EV isolation methods and commercial EV kits for exosomal RNA and protein enrichment. EXO-NET has the potential to revolutionise the performance of EV-based liquid biopsies for researchers and to underpin the development of INOVIQ's exosome-based diagnostics pipeline for the earlier and more accurate detection of cancer and other diseases."

The Scientific Statement titled "*Extracellular Vesicles and Their Emerging Roles as Cellular Messengers in Endocrinology: An Endocrine Society Scientific Statement*", was published online in *Endocrine Reviews*, available at <https://doi.org/10.1210/endrev/bnac009>.

Scientific Statements explore the scientific basis of disease, discuss how this knowledge can be applied in clinical practice, and identify areas that require additional research. The Endocrine Society selects topics based on their emerging scientific impact on disease and their clinical relevance to the general population. Scientific Statements are developed by a Task Force of experts with review by committees of the Endocrine Society.¹

¹ <https://www.endocrine.org/advancing-research/scientific-statements>

Authorised by the Company Secretary, Tony Di Pietro.

- ENDS -

COMPANY CONTACTS

Dr Learne Hinch
Chief Executive Officer
E lhinch@inoviq.com
M +61 400 414 416

Dr Geoff Cumming
Non-executive Chairman
E geoff.cumming@inoviq.com
M +61 417 203 021

Jane Lowe
IR Department
E jane.lowe@irdepartment.com.au
M +61 411 117 774

ABOUT INOVIQ LTD

INOVIQ Ltd (ASX:IIQ) (**INOVIQ**) is developing and commercialising innovative diagnostic and exosome-based products to improve the diagnosis and treatment of cancer and other diseases. The Company has commercialised the hTERT test used as an adjunct to urine cytology testing for bladder cancer and the EXO-NET pan-exosome capture tool for research purposes. Our cancer diagnostic pipeline includes blood tests in development for earlier detection and monitoring of ovarian, breast, prostate, and other cancers. For more information on INOVIQ, see www.inoviq.com.

FORWARD LOOKING STATEMENTS

This announcement contains certain 'forward-looking statements' within the meaning of the securities laws of applicable jurisdictions. Forward-looking statements can generally be identified by the use of forward-looking words such as 'may', 'should', 'expect', 'anticipate', 'estimate', 'scheduled' or 'continue' or the negative version of them or comparable terminology. Any forecasts or other forward-looking statements contained in this announcement are subject to known and unknown risks and uncertainties and may involve significant elements of subjective judgment and assumptions as to future events which may or may not be correct. There are usually differences between forecast and actual results because events and actual circumstances frequently do not occur as forecast and these differences may be material. The Company does not give any representation, assurance or guarantee that the occurrence of the events expressed or implied in any forward-looking statements in this announcement will actually occur and you are cautioned not to place undue reliance on forward-looking statements.